Toleranzia selects drug candidate for continued development within the Eurostars project

20 October - 2015

Toleranzia AB (”Toleranzia”) today announces that the company has selected a drug candidate, based on data from studies in animal disease models and on patient material from myasthenia gravis patients. The large scale manufacturing process will be performed by Biotechpharma, a Lithuanian company that Toleranzia collaborates with within the Eurostars project. The drug candidate (MG-tolerogen) will be manufactured in sufficient quantities and with the quality necessary to conduct formulation and stability studies as well as the safety and toxicology studies that are a prerequisite for a continued development towards clinical studies is man.

Björn Löwenadler, CEO of Toleranzia, comments

– We are very pleased to have selected our first drug candidate and that we now within the framework of the Eurostars project stand well prepared to start large scale manufacturing in collaboration with Biotechpharma. Simultaneously, we continue to broaden and deepen our understanding of myasthenia gravis through ongoing immunological studies that Toleranzia conducts on cell material from patients in collaboration with clinical expertise at the Sahlgrenska University hospital. These studies aim to further support our preclinical program and provide valuable information regarding design of forthcoming clinical studies.

For more information about Toleranzia, please contact:

Björn Löwenadler, CEO
Phone: +46 70-631 00 30
E-mail: bjorn.lowenadler@toleranzia.com


About the company

Toleranzia AB (556877-2866) has developed a platform technology for treatment of autoimmune diseases. The company´s main project is directed towards an autoimmune neuromuscular disease, myasthenia gravis, with a significant need for an effective treatment and an extensive market potential, for which Toleranzia has been granted Orphan Drug Designation in both EU and US. The platform technology enables development of therapies that target the root cause of the disease – not just the symptoms, which is the mainstay of current treatment. In addition to myasthenia gravis, the platform technology has been evaluated in three further disease indications – rheumatoid arthritis, multiple sclerosis and type 1 diabetes, where positive treatment effects have been obtained in disease-relevant animal models. Toleranzia was founded by researchers at the University of Gothenburg. The company has operations at the Biotech center in Gothenburg. Further reading at: www.toleranzia.com.